Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

Surface Plasmon Resonance (SPR) provides label-free, real-time quantitative data on the binding kinetics between an adeno-associated virus (AAV) capsid and its target cell surface receptors. This analysis is a direct measure of a vector’s biological activity and is a component of a comprehensive characterization package for regulatory submissions. Measuring binding affinity (KD), association rates (ka), and dissociation rates (kd) provides mechanistic insight into vector tropism, potency, and consistency between manufacturing lots.

The Role of Receptor Binding in AAV Vector Potency

The binding kinetics of an AAV capsid to its target cell surface receptor are a primary determinant of vector tropism and subsequent transduction efficiency. A vector that fails to engage its intended receptor with sufficient affinity will not deliver its genetic payload effectively. This interaction is a foundational attribute that links the physical viral particle to its biological activity.

Characterizing this binding event provides a quantitative measure of vector function that can be used to assess the consistency of manufacturing lots and the impact of process changes. Understanding the specific epitopes involved in receptor engagement informs rational capsid engineering and de-risks downstream program development.

Quantitative Characterization with Surface Plasmon Resonance

SPR technology measures changes in refractive index at the surface of a sensor chip to monitor molecular interactions. For AAV analysis, a purified receptor protein is typically immobilized on the chip, and the AAV vector is flowed over the surface as the analyte.

The process provides direct measurement of:

• Association (on-rate): The rate at which the AAV capsid binds to the immobilized receptor.

• Dissociation (off-rate): The rate at which the AAV-receptor complex decays.

• Affinity (KD): The equilibrium constant that defines the strength of the interaction.

This level of kinetic detail provides a functional signature for a given AAV product.

Correlating Binding Affinity with In Vivo Performance

Analytical data from SPR assays correlate directly with biological outcomes. Research identifying terminal galactose as a key receptor for AAV9 showed that modifying receptor availability on target cells could enhance in vivo gene transfer (PMID: 21576824). This finding highlights the direct relationship between receptor engagement and therapeutic efficacy, reinforcing the value of precise binding measurements during vector development.

An understanding of specific binding epitopes is also fundamental to vector design and manufacturing. The identification of a binding epitope for affinity resins showed that modifying a single residue could improve purification without affecting vector potency (PMID: 26605372). This principle extends to therapeutic interactions: a deep understanding of the residues governing receptor binding allows for the rational design of capsids with enhanced targeting or immune-evasive properties.

Robust AAV characterization programs are built upon an integrated knowledge of both vector production and advanced analytical methods.

Applications in AAV Product Development and Lot Release

Within our >100,000 sq ft facility, SPR assays are integrated into a broader GxP-compliant analytical strategy to support programs on an 18-24 month timeline to IND.

• Candidate Selection: Comparing the binding kinetics of multiple engineered capsids to select candidates with the optimal target engagement profile.

• Comparability Studies: Assessing the impact of manufacturing process changes (e.g., scale-up, purification methods) on the vector’s receptor binding function.

• Lot Release & Stability Testing: Using binding affinity as a quantitative potency metric to ensure lot-to-lot consistency and monitor product stability over time.

This data forms a key part of the CMC (Chemistry, Manufacturing, and Controls) data package required for regulatory submissions in the US and Europe.